TrialEuropean heart journal2021

Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.

Milton Packer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.